Herzass (Acetylsalicylic Acid)

Herzass is indicated for several common clinical situations where pain, fever, inflammation, or platelet inhibition are concerns.

• Relief of mild to moderate pain such as headache, toothache, or musculoskeletal discomfort.
• Reduction of fever associated with infections or inflammatory conditions.
• Management of inflammatory disorders, including arthritis and soft‑tissue inflammation.
• Primary or secondary prevention of cardiovascular events by inhibiting platelet aggregation.
• Adjunct therapy in acute coronary syndromes or after certain surgical procedures.

• Acetylsalicylic acid irreversibly acetylates the cyclooxygenase‑1 (COX‑1) enzyme, preventing the conversion of arachidonic acid to prostaglandin G2 and subsequently to prostaglandins and thromboxane A2. The reduction in prostaglandins diminishes pain, fever, and inflammation, while the decrease in thromboxane A2 impairs platelet aggregation, providing antiplatelet effects.

Herzass may cause a range of adverse reactions, from mild and transient to serious and potentially life‑threatening.

Common

• Gastrointestinal discomfort, including dyspepsia or heartburn.
• Nausea or mild vomiting.
• Minor bruising or prolonged bleeding from cuts.
• Headache or dizziness.

Serious

• Gastrointestinal ulceration or bleeding.
• Severe allergic reactions such as anaphylaxis or angioedema.
• Asthma exacerbation triggered by aspirin sensitivity.
• Renal impairment or acute kidney injury.
• Hepatic dysfunction in susceptible individuals.

Before initiating Herzass, certain health factors should be evaluated to minimize risk.

• History of peptic ulcer disease, gastrointestinal bleeding, or gastritis.
• Known bleeding disorders or concurrent anticoagulant therapy.
• Asthma or aspirin‑sensitive respiratory conditions.
• Impaired kidney or liver function.
• Pregnancy, especially the third trimester, and lactation.
• Use in children or adolescents with viral infections due to Reye's syndrome risk.
• Excessive alcohol consumption, which can increase gastrointestinal toxicity.

Herzass can interact with a variety of medicines, altering efficacy or safety.

Avoid

• Other NSAIDs, including ibuprofen and naproxen, which increase gastrointestinal risk.
• Anticoagulants such as warfarin or direct oral anticoagulants, heightening bleeding potential.
• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents.
• Corticosteroids, which together raise ulcer risk.
• Alcohol, due to additive gastric irritation.

Use with caution

• Antihypertensive drugs, as aspirin may reduce their effectiveness.
• Diuretics and ACE inhibitors, which can affect renal function.
• Lithium, where aspirin may increase lithium levels.
• Methotrexate, potentially raising its toxicity.
• Live vaccines, because antiplatelet activity may alter immune response.